共 36 条
- [21] A phase 1 study of AMG 199, a half-life extended bispecific T-cell engager (HLE BiTE®) immune therapy, targeting MUC17 in patients with gastric and gastroesophageal junction cancerANNALS OF ONCOLOGY, 2020, 31 : S114 - S114Lordick, F.论文数: 0 引用数: 0 h-index: 0机构: Univ Hosp Leipzig, Univ Canc Ctr Leipzig, Leipzig, Germany Univ Hosp Leipzig, Univ Canc Ctr Leipzig, Leipzig, GermanyBuxo Orra, E.论文数: 0 引用数: 0 h-index: 0机构: Hosp Quiron Salud, Barcelona, Spain Univ Hosp Leipzig, Univ Canc Ctr Leipzig, Leipzig, GermanyCervantes, A.论文数: 0 引用数: 0 h-index: 0机构: Inst Valenciano Oncol IVO 1, Valencia, Spain Univ Hosp Leipzig, Univ Canc Ctr Leipzig, Leipzig, GermanyDayyani, F.论文数: 0 引用数: 0 h-index: 0机构: Univ Calif Irvine, Med Ctr, Orange, CA USA Univ Hosp Leipzig, Univ Canc Ctr Leipzig, Leipzig, GermanyRocha-Lima, C.论文数: 0 引用数: 0 h-index: 0机构: Wake Forest Baptist Med Ctr, Winston Salem, NC USA Univ Hosp Leipzig, Univ Canc Ctr Leipzig, Leipzig, GermanyGreil, R.论文数: 0 引用数: 0 h-index: 0机构: Paracelsus Med Univ, Salzburg, Austria Univ Hosp Leipzig, Univ Canc Ctr Leipzig, Leipzig, Germanyvan Laarhoven, H.论文数: 0 引用数: 0 h-index: 0机构: Univ Amsterdam, Acad Med Ctr, Amsterdam, Netherlands Univ Hosp Leipzig, Univ Canc Ctr Leipzig, Leipzig, GermanyLorenzen, S.论文数: 0 引用数: 0 h-index: 0机构: Tech Univ Munich, Munich, Germany Univ Hosp Leipzig, Univ Canc Ctr Leipzig, Leipzig, GermanyKischel, R.论文数: 0 引用数: 0 h-index: 0机构: Amgen Europe GmbH, European Med, Rotkreuz, Switzerland Univ Hosp Leipzig, Univ Canc Ctr Leipzig, Leipzig, GermanyShitara, K.论文数: 0 引用数: 0 h-index: 0机构: Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan Univ Hosp Leipzig, Univ Canc Ctr Leipzig, Leipzig, GermanyChao, J.论文数: 0 引用数: 0 h-index: 0机构: City Hope Natl Med Ctr, Comprehens Canc Ctr, Dept Med Oncol & Therapeut Res, Duarte, CA USA Univ Hosp Leipzig, Univ Canc Ctr Leipzig, Leipzig, Germany
- [22] Updated results from a phase 1 study of AMG 757, a half-life extended bispecific T-cell engager (BiTE) immuno-oncology therapy against delta-like ligand 3 (DLL3), in small cell lung cancer (SCLC).JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)Owonikoko, Taofeek K.论文数: 0 引用数: 0 h-index: 0Champiat, Stephane论文数: 0 引用数: 0 h-index: 0Johnson, Melissa Lynne论文数: 0 引用数: 0 h-index: 0Govindan, Ramaswamy论文数: 0 引用数: 0 h-index: 0Izumi, Hiroki论文数: 0 引用数: 0 h-index: 0Lai, W. Victoria Victoria论文数: 0 引用数: 0 h-index: 0Borghaei, Hossein论文数: 0 引用数: 0 h-index: 0Boyer, Michael J.论文数: 0 引用数: 0 h-index: 0Boosman, Rene J.论文数: 0 引用数: 0 h-index: 0Hummel, Horst-Dieter论文数: 0 引用数: 0 h-index: 0Blackhall, Fiona Helen论文数: 0 引用数: 0 h-index: 0Reguart, Noemi论文数: 0 引用数: 0 h-index: 0Dowlati, Afshin论文数: 0 引用数: 0 h-index: 0Zhang, Yiran论文数: 0 引用数: 0 h-index: 0Mukherjee, Sujoy论文数: 0 引用数: 0 h-index: 0Minocha, Mukul论文数: 0 引用数: 0 h-index: 0Zhou, Yanchen论文数: 0 引用数: 0 h-index: 0Shetty, Aditya论文数: 0 引用数: 0 h-index: 0Sadraei, Nooshin Hashemi论文数: 0 引用数: 0 h-index: 0Paz-Ares, Luis G.论文数: 0 引用数: 0 h-index: 0
- [23] Phase I study of AMG 160, a half-life extended bispecific T-cell engager (HLE BiTE immune therapy) targeting prostate-specific membrane antigen, in patients with metastatic castration-resistant prostate cancer (mCRPC).JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)Ben Tran论文数: 0 引用数: 0 h-index: 0机构: Peter MacCallum Canc Ctr, Melbourne, Vic, AustraliaHorvath, Lisa论文数: 0 引用数: 0 h-index: 0机构: Peter MacCallum Canc Ctr, Melbourne, Vic, AustraliaRettig, Matthew论文数: 0 引用数: 0 h-index: 0机构: Peter MacCallum Canc Ctr, Melbourne, Vic, AustraliaFizazi, Karim论文数: 0 引用数: 0 h-index: 0机构: Peter MacCallum Canc Ctr, Melbourne, Vic, AustraliaLolkema, Martijn P.论文数: 0 引用数: 0 h-index: 0机构: Peter MacCallum Canc Ctr, Melbourne, Vic, AustraliaDorff, Tanya B.论文数: 0 引用数: 0 h-index: 0机构: Peter MacCallum Canc Ctr, Melbourne, Vic, AustraliaGreil, Richard论文数: 0 引用数: 0 h-index: 0机构: Peter MacCallum Canc Ctr, Melbourne, Vic, AustraliaMachiels, Jean-Pascal H.论文数: 0 引用数: 0 h-index: 0机构: Peter MacCallum Canc Ctr, Melbourne, Vic, AustraliaAutio, Karen A.论文数: 0 引用数: 0 h-index: 0机构: Peter MacCallum Canc Ctr, Melbourne, Vic, AustraliaRottey, Sylvie论文数: 0 引用数: 0 h-index: 0机构: Peter MacCallum Canc Ctr, Melbourne, Vic, AustraliaAdra, Nabil论文数: 0 引用数: 0 h-index: 0机构: Peter MacCallum Canc Ctr, Melbourne, Vic, AustraliaGarje, Rohan论文数: 0 引用数: 0 h-index: 0机构: Peter MacCallum Canc Ctr, Melbourne, Vic, AustraliaRoncolato, Felicia论文数: 0 引用数: 0 h-index: 0机构: Peter MacCallum Canc Ctr, Melbourne, Vic, AustraliaTagawa, Scott T.论文数: 0 引用数: 0 h-index: 0机构: Peter MacCallum Canc Ctr, Melbourne, Vic, AustraliaShariat, Shahrokh F.论文数: 0 引用数: 0 h-index: 0机构: Peter MacCallum Canc Ctr, Melbourne, Vic, AustraliaSalvati, Mark论文数: 0 引用数: 0 h-index: 0机构: Peter MacCallum Canc Ctr, Melbourne, Vic, AustraliaPoon, Shirley论文数: 0 引用数: 0 h-index: 0机构: Peter MacCallum Canc Ctr, Melbourne, Vic, AustraliaKouros-Mehr, Hosein论文数: 0 引用数: 0 h-index: 0机构: Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
- [24] Phase I study of AMG 757, a delta-like ligand 3 (DLL3) targeting, half-life extended bispecific T-cell engager immuno-oncology therapy, in small cell lung cancer (SCLC)JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S720 - S721Paz-Ares, L.论文数: 0 引用数: 0 h-index: 0机构: Univ Hosp 12 Octubre, CNIO H12o Lung Canc Unit, Madrid, Spain Univ Hosp 12 Octubre, CNIO H12o Lung Canc Unit, Madrid, SpainOwonikoko, T. K.论文数: 0 引用数: 0 h-index: 0机构: Emory Univ, Sch Med, Dept Hematol & Med Oncol, Atlanta, GA USA Univ Hosp 12 Octubre, CNIO H12o Lung Canc Unit, Madrid, SpainJohnson, M.论文数: 0 引用数: 0 h-index: 0机构: Tennessee Oncol, Sarah Cannon Res Inst, Lung Canc Res, Nashville, TN USA Univ Hosp 12 Octubre, CNIO H12o Lung Canc Unit, Madrid, Spain论文数: 引用数: h-index:机构:Izumi, H.论文数: 0 引用数: 0 h-index: 0机构: Natl Canc Ctr Hosp East, Dept Thorac Oncol, Kashiwa, Chiba, Japan Univ Hosp 12 Octubre, CNIO H12o Lung Canc Unit, Madrid, SpainLai, V.论文数: 0 引用数: 0 h-index: 0机构: Mem Sloan Kettering Canc Ctr, Div Solid Tumor Oncol, Dept Med, Thorac Oncol Serv, 1275 York Ave, New York, NY 10021 USA Univ Hosp 12 Octubre, CNIO H12o Lung Canc Unit, Madrid, SpainBorghaei, H.论文数: 0 引用数: 0 h-index: 0机构: Fox Chase Canc Ctr, Dept Hematol Oncol, 7701 Burholme Ave, Philadelphia, PA 19111 USA Univ Hosp 12 Octubre, CNIO H12o Lung Canc Unit, Madrid, SpainBoyer, M.论文数: 0 引用数: 0 h-index: 0机构: Chris OBrien Lifehouse, Camperdown, NSW, Australia Univ Hosp 12 Octubre, CNIO H12o Lung Canc Unit, Madrid, SpainBoosman, R. J.论文数: 0 引用数: 0 h-index: 0机构: Netherlands Canc Inst, Amsterdam, Netherlands Univ Hosp 12 Octubre, CNIO H12o Lung Canc Unit, Madrid, SpainHummel, H-D.论文数: 0 引用数: 0 h-index: 0机构: Univ Hosp Wurzburg, Comprehens Canc Ctr Mainfranken, Wurzburg, Germany Univ Hosp 12 Octubre, CNIO H12o Lung Canc Unit, Madrid, SpainBlackhall, F.论文数: 0 引用数: 0 h-index: 0机构: Christie NHS Fdn Trust, Dept Med Oncol, Manchester, Lancs, England Univ Hosp 12 Octubre, CNIO H12o Lung Canc Unit, Madrid, SpainDowlati, A.论文数: 0 引用数: 0 h-index: 0机构: Univ Hosp Cleveland, Seidman Canc, Cleveland, OH 44106 USA Case Western Reserve Univ, Cleveland, OH 44106 USA Univ Hosp 12 Octubre, CNIO H12o Lung Canc Unit, Madrid, SpainZhang, Y.论文数: 0 引用数: 0 h-index: 0机构: Amgen Inc, Thousand Oaks, CA 91320 USA Univ Hosp 12 Octubre, CNIO H12o Lung Canc Unit, Madrid, SpainMukherjee, S.论文数: 0 引用数: 0 h-index: 0机构: Amgen Inc, Thousand Oaks, CA 91320 USA Univ Hosp 12 Octubre, CNIO H12o Lung Canc Unit, Madrid, SpainSable, B.论文数: 0 引用数: 0 h-index: 0机构: Amgen Inc, Thousand Oaks, CA 91320 USA Univ Hosp 12 Octubre, CNIO H12o Lung Canc Unit, Madrid, SpainPati, A.论文数: 0 引用数: 0 h-index: 0机构: Amgen Inc, Thousand Oaks, CA 91320 USA Univ Hosp 12 Octubre, CNIO H12o Lung Canc Unit, Madrid, SpainShetty, A.论文数: 0 引用数: 0 h-index: 0机构: Amgen Inc, Thousand Oaks, CA 91320 USA Univ Hosp 12 Octubre, CNIO H12o Lung Canc Unit, Madrid, SpainSadraei, N. Hashemi论文数: 0 引用数: 0 h-index: 0机构: Amgen Inc, Thousand Oaks, CA 91320 USA Univ Hosp 12 Octubre, CNIO H12o Lung Canc Unit, Madrid, Spain论文数: 引用数: h-index:机构:
- [25] DeLLphi-303: Phase Ib first-line combination study of tarlatamab, a DLL3-targeting half-life extended bispecific T-cell engager (HLE BiTE®), with carboplatin, etoposide, and PD-L1 inhibition in extensive stage small cell lung cancer (ES-SCLC)ANNALS OF ONCOLOGY, 2022, 33 (07) : S1255 - S1255Gadgeel, S. M.论文数: 0 引用数: 0 h-index: 0机构: Henry Ford Canc Inst, Oncol Dept, Detroit, MI USA Henry Ford Canc Inst, Oncol Dept, Detroit, MI USAAl-Mondhiry, J.论文数: 0 引用数: 0 h-index: 0机构: Univ Southern Calif, Div Oncol, Norris Comprehens Canc Ctr, Los Angeles, CA USA Henry Ford Canc Inst, Oncol Dept, Detroit, MI USAAhn, M-J.论文数: 0 引用数: 0 h-index: 0机构: Henry Ford Canc Inst, Oncol Dept, Detroit, MI USAKim, S-W.论文数: 0 引用数: 0 h-index: 0机构: Univ Ulsan, Dept Oncol, Asan Med Ctr, Coll Med, Seoul, South Korea Henry Ford Canc Inst, Oncol Dept, Detroit, MI USAPaz-Ares, L.论文数: 0 引用数: 0 h-index: 0机构: Hosp Univ 12 Octubre, Med Oncol Dept, CNIO H120 Lung Canc Unit, Ciberonc, Edificio Matern, Madrid, Spain Univ Complutense, Madrid, Spain Henry Ford Canc Inst, Oncol Dept, Detroit, MI USAPrenen, H.论文数: 0 引用数: 0 h-index: 0机构: UZA Univ Hosp Antwerp, Oncol Dept, Edegem, Belgium Henry Ford Canc Inst, Oncol Dept, Detroit, MI USABoyer, M.论文数: 0 引用数: 0 h-index: 0机构: Chris Obrien Lifehouse, Dept Med Oncol, Camperdown, NSW, Australia Henry Ford Canc Inst, Oncol Dept, Detroit, MI USABustamante Alvarez, J. G.论文数: 0 引用数: 0 h-index: 0机构: West Virginia Univ, Med Oncol Dept, Morgantown, WV USA Henry Ford Canc Inst, Oncol Dept, Detroit, MI USASolomon, B.论文数: 0 引用数: 0 h-index: 0机构: Avera McKennan Hosp & Univ Hlth Ctr, Hematol & Oncol, Sioux Falls, SD USA Henry Ford Canc Inst, Oncol Dept, Detroit, MI USAHuang, S.论文数: 0 引用数: 0 h-index: 0机构: Amgen Inc, Biostat, Thousand Oaks, CA USA Henry Ford Canc Inst, Oncol Dept, Detroit, MI USAMinocha, M.论文数: 0 引用数: 0 h-index: 0机构: Amgen Inc, Clin Pharmacol, Thousand Oaks, CA USA Henry Ford Canc Inst, Oncol Dept, Detroit, MI USAKistler, M.论文数: 0 引用数: 0 h-index: 0机构: Amgen Inc, Res & Dev, Thousand Oaks, CA USA Henry Ford Canc Inst, Oncol Dept, Detroit, MI USASadraei, N. Hashemi论文数: 0 引用数: 0 h-index: 0机构: Amgen Inc, Res & Dev, Thousand Oaks, CA USA Henry Ford Canc Inst, Oncol Dept, Detroit, MI USA
- [26] Phase I study of AMG 160, a half-life extended bispecific T-cell engager (HLE BiTE) immune therapy targeting prostate-specific membrane antigen (PSMA), in patients with metastatic castration-resistant prostate cancer (mCRPC)JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)Tran, Ben论文数: 0 引用数: 0 h-index: 0机构: Peter MacCallum Canc Ctr, Melbourne, Vic, AustraliaHorvath, Lisa论文数: 0 引用数: 0 h-index: 0机构: Peter MacCallum Canc Ctr, Melbourne, Vic, AustraliaDorff, Tanya B.论文数: 0 引用数: 0 h-index: 0机构: Peter MacCallum Canc Ctr, Melbourne, Vic, AustraliaGreil, Richard论文数: 0 引用数: 0 h-index: 0机构: Peter MacCallum Canc Ctr, Melbourne, Vic, AustraliaMachiels, Jean-Pascal H.论文数: 0 引用数: 0 h-index: 0机构: Peter MacCallum Canc Ctr, Melbourne, Vic, AustraliaRoncolato, Felicia论文数: 0 引用数: 0 h-index: 0机构: Peter MacCallum Canc Ctr, Melbourne, Vic, AustraliaAutio, Karen A.论文数: 0 引用数: 0 h-index: 0机构: Peter MacCallum Canc Ctr, Melbourne, Vic, AustraliaRettig, Matthew论文数: 0 引用数: 0 h-index: 0机构: Peter MacCallum Canc Ctr, Melbourne, Vic, AustraliaFizazi, Karim论文数: 0 引用数: 0 h-index: 0机构: Peter MacCallum Canc Ctr, Melbourne, Vic, AustraliaLolkema, Martijn P.论文数: 0 引用数: 0 h-index: 0机构: Peter MacCallum Canc Ctr, Melbourne, Vic, AustraliaFermin, Anthony C.论文数: 0 引用数: 0 h-index: 0机构: Peter MacCallum Canc Ctr, Melbourne, Vic, AustraliaSalvati, Mark论文数: 0 引用数: 0 h-index: 0机构: Peter MacCallum Canc Ctr, Melbourne, Vic, AustraliaKouros-Mehr, Hosein论文数: 0 引用数: 0 h-index: 0机构: Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
- [27] Phase II study of tarlatamab, a half-life extended bispecific T-cell engager (HLE BiTE®) immuno-oncology therapy targeting DLL3, in third-line or later small cell lung cancer (SCLC)ANNALS OF ONCOLOGY, 2022, 33 : S103 - S104Ramalingam, S. S.论文数: 0 引用数: 0 h-index: 0机构: Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USAAhn, M-J.论文数: 0 引用数: 0 h-index: 0机构: Sungkyunkwan Univ, Sch Med, Samsung Med Ctr SMC, Seoul, South Korea Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USAAkamatsu, H.论文数: 0 引用数: 0 h-index: 0机构: Wakayama Med Univ Hosp, Wakayama, Japan Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USABlackhall, F.论文数: 0 引用数: 0 h-index: 0机构: Christie NHS Fdn Trust, Manchester, Lancs, England Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USABorghaei, H.论文数: 0 引用数: 0 h-index: 0机构: Fox Chase Canc Ctr, 7701 Burholme Ave, Philadelphia, PA 19111 USA Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USAHummel, H-D.论文数: 0 引用数: 0 h-index: 0机构: Univ Wurzburg, Comprehens Canc Ctr Mainfranken, Translat Oncol Early Clin Trial Unit, Wurzburg, Germany Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USAJohnson, M.论文数: 0 引用数: 0 h-index: 0机构: Sarah Cannon Res Inst, Nashville, TN USA Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USAReck, M.论文数: 0 引用数: 0 h-index: 0机构: Airway Res Ctr North, German Ctr Lung Res, LungenClin, Grosshansdorf, Germany Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USAZhang, Y.论文数: 0 引用数: 0 h-index: 0机构: Amgen Inc, Thousand Oaks, CA 91320 USA Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USAJandial, D.论文数: 0 引用数: 0 h-index: 0机构: Amgen Inc, Thousand Oaks, CA 91320 USA Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USACheng, S.论文数: 0 引用数: 0 h-index: 0机构: Amgen Inc, Thousand Oaks, CA 91320 USA Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USAPaz-Ares, L.论文数: 0 引用数: 0 h-index: 0机构: Hosp Univ 12 Octubre, Madrid, Spain Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
- [28] A phase I study of AMG 160, a half-life extended bispecific T cell engager (HLE BiTE) immuno-oncology therapy targeting PSMA, in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)ANNALS OF ONCOLOGY, 2019, 30 : 353 - 353Tran, B.论文数: 0 引用数: 0 h-index: 0机构: Peter MacCallum Canc Ctr, Dept Med Oncol, Melbourne, Vic, Australia Peter MacCallum Canc Ctr, Dept Med Oncol, Melbourne, Vic, AustraliaKouros-Mehr, H.论文数: 0 引用数: 0 h-index: 0机构: Amgen Inc, Early Dev Oncol, Thousand Oaks, CA 91320 USA Peter MacCallum Canc Ctr, Dept Med Oncol, Melbourne, Vic, AustraliaFermin, A.论文数: 0 引用数: 0 h-index: 0机构: Amgen Inc, Early Dev Oncol, Thousand Oaks, CA 91320 USA Peter MacCallum Canc Ctr, Dept Med Oncol, Melbourne, Vic, AustraliaHorvath, L.论文数: 0 引用数: 0 h-index: 0机构: Chris OBrien Lifehouse, Dept Med Oncol, Camperdown, NSW, Australia Peter MacCallum Canc Ctr, Dept Med Oncol, Melbourne, Vic, AustraliaRoncolato, F.论文数: 0 引用数: 0 h-index: 0机构: Scientia Clin Res Ltd, Nelune Comprehens Canc Ctr, Randwick, NSW, Australia Peter MacCallum Canc Ctr, Dept Med Oncol, Melbourne, Vic, AustraliaRettig, M.论文数: 0 引用数: 0 h-index: 0机构: Univ Calif Los Angeles, Dept Med & Urol, Los Angeles, CA USA Peter MacCallum Canc Ctr, Dept Med Oncol, Melbourne, Vic, AustraliaDorff, T.论文数: 0 引用数: 0 h-index: 0机构: City Hope Natl Med Ctr, Dept Med Oncol & Dev Therapeut, 1500 E Duarte Rd, Duarte, CA 91010 USA Peter MacCallum Canc Ctr, Dept Med Oncol, Melbourne, Vic, AustraliaTagawa, S. T.论文数: 0 引用数: 0 h-index: 0机构: Weill Cornell Med Coll, Div Hematol & Oncol, New York, NY USA Peter MacCallum Canc Ctr, Dept Med Oncol, Melbourne, Vic, AustraliaSubudhi, S. K.论文数: 0 引用数: 0 h-index: 0机构: Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX 77030 USA Peter MacCallum Canc Ctr, Dept Med Oncol, Melbourne, Vic, AustraliaAntonarakis, E. S.论文数: 0 引用数: 0 h-index: 0机构: Johns Hopkins Univ, Dept Med Oncol, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA Peter MacCallum Canc Ctr, Dept Med Oncol, Melbourne, Vic, AustraliaArmstrong, A. J.论文数: 0 引用数: 0 h-index: 0机构: Duke Univ, Dept Med, Duke Canc Inst, Ctr Prostate & Urol Canc, Durham, NC USA Peter MacCallum Canc Ctr, Dept Med Oncol, Melbourne, Vic, AustraliaPetrylak, D. P.论文数: 0 引用数: 0 h-index: 0机构: Yale Canc Ctr, Dept Med Oncol, New Haven, CT USA Peter MacCallum Canc Ctr, Dept Med Oncol, Melbourne, Vic, AustraliaFizazi, K.论文数: 0 引用数: 0 h-index: 0机构: Gustave Roussy Canc Ctr, Canc Med, Villefranche Sur Mer, France Peter MacCallum Canc Ctr, Dept Med Oncol, Melbourne, Vic, AustraliaSalvati, M. E.论文数: 0 引用数: 0 h-index: 0机构: Amgen Inc, Early Dev Oncol, Thousand Oaks, CA 91320 USA Peter MacCallum Canc Ctr, Dept Med Oncol, Melbourne, Vic, AustraliaScher, H. I.论文数: 0 引用数: 0 h-index: 0机构: Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10021 USA Peter MacCallum Canc Ctr, Dept Med Oncol, Melbourne, Vic, Australia
- [29] Results from a phase I study of AMG 160, a half-life extended (HLE), PSMA-targeted, bispecific T-cell engager (BiTE®) immune therapy for metastatic castration-resistant prostate cancer (mCRPC)ANNALS OF ONCOLOGY, 2020, 31 : S507 - S507Tran, B.论文数: 0 引用数: 0 h-index: 0机构: Peter MacCallum Canc Ctr, Med Oncol Dept, Melbourne, Vic, Australia Peter MacCallum Canc Ctr, Med Oncol Dept, Melbourne, Vic, AustraliaHorvath, L.论文数: 0 引用数: 0 h-index: 0机构: Chris OBrien Lifehouse, Med Oncol, Camperdown, NSW, Australia Peter MacCallum Canc Ctr, Med Oncol Dept, Melbourne, Vic, AustraliaDorff, T.论文数: 0 引用数: 0 h-index: 0机构: City Hope Natl Med Ctr, Internal Med, Duarte, CA USA Peter MacCallum Canc Ctr, Med Oncol Dept, Melbourne, Vic, AustraliaRettig, M.论文数: 0 引用数: 0 h-index: 0机构: Univ Calif Los Angeles, Med Oncol, Los Angeles, CA USA Peter MacCallum Canc Ctr, Med Oncol Dept, Melbourne, Vic, AustraliaLolkema, M. P.论文数: 0 引用数: 0 h-index: 0机构: Erasmus MC, Med Oncol, Rotterdam, Netherlands Peter MacCallum Canc Ctr, Med Oncol Dept, Melbourne, Vic, AustraliaMachiels, J-P.论文数: 0 引用数: 0 h-index: 0机构: Clin Univ St Luc, Oncol, Brussels, Belgium Peter MacCallum Canc Ctr, Med Oncol Dept, Melbourne, Vic, AustraliaRottey, S.论文数: 0 引用数: 0 h-index: 0机构: Univ Ghent, Drug Res Unit Ghent, Ghent, Belgium Peter MacCallum Canc Ctr, Med Oncol Dept, Melbourne, Vic, AustraliaAutio, K.论文数: 0 引用数: 0 h-index: 0机构: Mem Sloan Kettering Canc Ctr, Med Oncol, 1275 York Ave, New York, NY 10021 USA Peter MacCallum Canc Ctr, Med Oncol Dept, Melbourne, Vic, AustraliaGreil, R.论文数: 0 引用数: 0 h-index: 0机构: Paracelsus Med Univ Salzburg, Med Dept 3, Salzburg Canc Res Inst CCCIT, Salzburg, Austria Canc Cluster, Salzburg, Austria Peter MacCallum Canc Ctr, Med Oncol Dept, Melbourne, Vic, AustraliaAdra, N.论文数: 0 引用数: 0 h-index: 0机构: Indiana Univ Sch Med, Urol, Indianapolis, IN 46202 USA Peter MacCallum Canc Ctr, Med Oncol Dept, Melbourne, Vic, AustraliaLemech, C.论文数: 0 引用数: 0 h-index: 0机构: Scientia Clin Res, Randwick, NSW, Australia Peter MacCallum Canc Ctr, Med Oncol Dept, Melbourne, Vic, AustraliaMinocha, M.论文数: 0 引用数: 0 h-index: 0机构: Amgen Inc, Clin Pharmacol Modeling Simulat, Thousand Oaks, CA 91320 USA Peter MacCallum Canc Ctr, Med Oncol Dept, Melbourne, Vic, AustraliaCheng, F-C.论文数: 0 引用数: 0 h-index: 0机构: Amgen Inc, Biostat Sci, Thousand Oaks, CA 91320 USA Peter MacCallum Canc Ctr, Med Oncol Dept, Melbourne, Vic, AustraliaKouros-Mehr, H.论文数: 0 引用数: 0 h-index: 0机构: Amgen Inc, Translat Med, Thousand Oaks, CA 91320 USA Peter MacCallum Canc Ctr, Med Oncol Dept, Melbourne, Vic, AustraliaFizazi, K.论文数: 0 引用数: 0 h-index: 0机构: Inst Gustave Roussy, Canc Med Dept, Villejuif, France Peter MacCallum Canc Ctr, Med Oncol Dept, Melbourne, Vic, Australia
- [30] Preliminary phase I results from a first-in-human study of ZG006, a trispecific anti-T cell engager targeting CD3/DLL3/DLL3, as monotherapy in patients with advanced small cell lung cancer or neuroendocrine carcinomaANNALS OF ONCOLOGY, 2024, 35 : S532 - S533Wang, Q.论文数: 0 引用数: 0 h-index: 0机构: Zhengzhou Univ, Affiliated Canc Hosp, Henan Canc Hosp, Dept Resp, Zhengzhou, Peoples R China Zhengzhou Univ, Affiliated Canc Hosp, Henan Canc Hosp, Dept Resp, Zhengzhou, Peoples R ChinaChai, X.论文数: 0 引用数: 0 h-index: 0机构: ChangSha TaiHe Hosp, Dept Oncol, Changsha, Peoples R China Zhengzhou Univ, Affiliated Canc Hosp, Henan Canc Hosp, Dept Resp, Zhengzhou, Peoples R ChinaLin, R.论文数: 0 引用数: 0 h-index: 0机构: Fujian Canc Hosp, Dept Abdominal Oncol, Fujian, Peoples R China Zhengzhou Univ, Affiliated Canc Hosp, Henan Canc Hosp, Dept Resp, Zhengzhou, Peoples R ChinaZheng, L.论文数: 0 引用数: 0 h-index: 0机构: Sichuan Univ, West China Hosp, Clin Trial Ctr, Chengdu, Peoples R China Zhengzhou Univ, Affiliated Canc Hosp, Henan Canc Hosp, Dept Resp, Zhengzhou, Peoples R ChinaCao, D.论文数: 0 引用数: 0 h-index: 0机构: Sichuan Univ, West China Hosp, Dept Abdominal Oncol, Chengdu, Peoples R China Zhengzhou Univ, Affiliated Canc Hosp, Henan Canc Hosp, Dept Resp, Zhengzhou, Peoples R ChinaQu, X.论文数: 0 引用数: 0 h-index: 0机构: China Med Univ, Hosp 1, Dept Med Oncol, Shenyang, Peoples R China Zhengzhou Univ, Affiliated Canc Hosp, Henan Canc Hosp, Dept Resp, Zhengzhou, Peoples R ChinaLiu, L.论文数: 0 引用数: 0 h-index: 0机构: Jilin Univ, China Japan Union Hosp, Phase Clin Trial Ctr 1, Changchun, Peoples R China Zhengzhou Univ, Affiliated Canc Hosp, Henan Canc Hosp, Dept Resp, Zhengzhou, Peoples R ChinaWu, L.论文数: 0 引用数: 0 h-index: 0机构: Shulan Hangzhou Hosp, Dept Hepatobiliary & Pancreat Surg, Hangzhou, Peoples R China Zhengzhou Univ, Affiliated Canc Hosp, Henan Canc Hosp, Dept Resp, Zhengzhou, Peoples R ChinaMou, H.论文数: 0 引用数: 0 h-index: 0机构: Shulan Hangzhou Hosp, Dept Oncol, Hangzhou, Peoples R China Zhengzhou Univ, Affiliated Canc Hosp, Henan Canc Hosp, Dept Resp, Zhengzhou, Peoples R ChinaXu, Q.论文数: 0 引用数: 0 h-index: 0机构: Zhejiang Canc Hosp, Dept Hepatobiliary & Pancreat Gastroenterol, Hangzhou, Peoples R China Zhengzhou Univ, Affiliated Canc Hosp, Henan Canc Hosp, Dept Resp, Zhengzhou, Peoples R ChinaShi, J.论文数: 0 引用数: 0 h-index: 0机构: Linyi Canc Hosp, Dept Med Oncol, Linyi, Shandong, Peoples R China Zhengzhou Univ, Affiliated Canc Hosp, Henan Canc Hosp, Dept Resp, Zhengzhou, Peoples R China